Division of Hematology and Oncology, Department of Medicine, Columbia University Medical Center, New York, New York, USA
Division of Hematology and Oncology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
Oncologist. 2017 Dec;22(12):1424-1426. doi: 10.1634/theoncologist.2017-0453. Epub 2017 Oct 5.
Many investigators have turned their efforts toward improving the gemcitabine/nab‐paclitaxel combination by the addition of a third agent. This commentary highlights efforts to date, including the Clinical Trial Results by Ko et al.: A Randomized Double‐Blinded Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastati Pancreatic Cancer: The RAINIER Trial.
许多研究人员致力于通过添加第三种药物来改进吉西他滨/纳布紫杉醇联合用药。这篇评论重点介绍了迄今为止的努力，包括 Ko 等人的临床试验结果：吉西他滨和纳布紫杉醇加 Apatorsen 或安慰剂治疗转移性胰腺癌患者的随机双盲 II 期试验：RAINIER 试验。
